最終更新日:2022/12/24

As another interleukin 12/23 antagonist, briakinumab, was withdrawn from further development in part due to concerns about cardiovascular safety, discussion has also emerged on cardiovascular safety of ustekinumab.

編集履歴(0)

Sentence quizzes to help you learn to read

編集履歴(0)

ログイン / 新規登録

 

アプリをダウンロード!
DiQt

DiQt(ディクト)

無料

★★★★★★★★★★